BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30463782)

  • 1. Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake Correlates with KRAS and EMT Gene Signatures in Operable Esophageal Adenocarcinoma.
    Heiden BT; Patel N; Nancarrow DJ; Hermann M; Brown RKJ; Orringer MB; Lin J; Chang AC; Carrott PW; Lynch WR; Zhao L; Beer DG; Reddy RM
    J Surg Res; 2018 Dec; 232():621-628. PubMed ID: 30463782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma.
    Takamochi K; Mogushi K; Kawaji H; Imashimizu K; Fukui M; Oh S; Itoh M; Hayashizaki Y; Ko W; Akeboshi M; Suzuki K
    PLoS One; 2017; 12(4):e0175622. PubMed ID: 28422979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer.
    Taylor MD; Smith PW; Brix WK; Wick MR; Theodosakis N; Swenson BR; Kozower BD; Jones DR
    Eur J Cardiothorac Surg; 2009 Apr; 35(4):699-705. PubMed ID: 19136271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.
    Hyun SH; Choi JY; Shim YM; Kim K; Lee SJ; Cho YS; Lee JY; Lee KH; Kim BT
    Ann Surg Oncol; 2010 Jan; 17(1):115-22. PubMed ID: 19826877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET intensity correlates with a hypoxic gene signature and other oncogenic abnormalities in operable non-small cell lung cancer.
    Heiden BT; Chen G; Hermann M; Brown RKJ; Orringer MB; Lin J; Chang AC; Carrott PW; Lynch WR; Zhao L; Beer DG; Reddy RM
    PLoS One; 2018; 13(7):e0199970. PubMed ID: 29966011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
    Yap WK; Chang YC; Tseng CK; Hsieh CH; Chao YK; Su PJ; Hou MM; Yang CK; Pai PC; Lin CR; Hsieh CE; Wu YY; Hung TM
    Dis Esophagus; 2017 Aug; 30(8):1-10. PubMed ID: 28575243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D; Hölscher AH; Dietlein M; Bollschweiler E; Baldus SE; Mönig SP; Metzger R; Schicha H; Schmidt M
    Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of
    Arnett ALH; Merrell KW; Macintosh EM; James SE; Nathan MA; Shen KR; Ravi K; Neben Wittich MA; Haddock MG; Hallemeier CL
    J Thorac Oncol; 2017 Jan; 12(1):121-128. PubMed ID: 27569732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
    Klayton T; Li T; Yu JQ; Keller L; Cheng J; Cohen SJ; Meropol NJ; Scott W; Xu-Welliver M; Konski A
    J Gastrointest Cancer; 2012 Dec; 43(4):612-8. PubMed ID: 22777832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations among KRAS Mutation, Microsatellite Instability, and 18F-FDG Uptake in Colon Cancer.
    Lee SS; Choi SJ; Park JS
    Asian Pac J Cancer Prev; 2022 Oct; 23(10):3501-3506. PubMed ID: 36308376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?
    Monjazeb AM; Riedlinger G; Aklilu M; Geisinger KR; Mishra G; Isom S; Clark P; Levine EA; Blackstock AW
    J Clin Oncol; 2010 Nov; 28(31):4714-21. PubMed ID: 20876421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response.
    Gerbaudo VH; Killoran JH; Kim CK; Hornick JL; Nowak JA; Enzinger PC; Mamon HJ
    Ann Nucl Med; 2018 Apr; 32(3):165-174. PubMed ID: 29332233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-fluorodeoxyglucose uptake predicts PKM2 expression in lung adenocarcinoma.
    Huang P; Zhao X; Xiao W; Dong Y; Hu G
    Oncotarget; 2017 Jun; 8(24):39618-39626. PubMed ID: 28489603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic values of mid-radiotherapy
    Kim N; Cho H; Yun M; Park KR; Lee CG
    Radiat Oncol; 2019 Feb; 14(1):27. PubMed ID: 30717809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours.
    Toba H; Kondo K; Sadohara Y; Otsuka H; Morimoto M; Kajiura K; Nakagawa Y; Yoshida M; Kawakami Y; Takizawa H; Kenzaki K; Sakiyama S; Bando Y; Tangoku A
    Eur J Cardiothorac Surg; 2013 Aug; 44(2):e105-12. PubMed ID: 23674658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is FDG-PET indicated for superficial esophageal cancer?
    Little SG; Rice TW; Bybel B; Mason DP; Murthy SC; Falk GW; Rybicki LA; Blackstone EH
    Eur J Cardiothorac Surg; 2007 May; 31(5):791-6. PubMed ID: 17337344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement.
    Iwamuro M; Okada H; Takata K; Shinagawa K; Fujiki S; Shiode J; Imagawa A; Araki M; Morito T; Nishimura M; Mizuno M; Inaba T; Suzuki S; Kawai Y; Yoshino T; Kawahara Y; Takaki A; Yamamoto K
    World J Gastroenterol; 2012 Nov; 18(44):6427-36; discussion p.6434. PubMed ID: 23197888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of fluorodeoxyglucose positron emission tomography/computed tomography and magnifying endoscopy with narrow band imaging in decision-making regarding the treatment strategy for esophageal squamous cell carcinoma.
    Toriyama K; Tajika M; Tanaka T; Ishihara M; Hirayama Y; Onishi S; Mizuno N; Kuwahara T; Okuno N; Matsumoto S; Sasaki E; Abe T; Yatabe Y; Hara K; Matsuo K; Tamaki T; Niwa Y
    World J Gastroenterol; 2019 Dec; 25(46):6767-6780. PubMed ID: 31857778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by
    Ikeno Y; Seo S; Iwaisako K; Yoh T; Nakamoto Y; Fuji H; Taura K; Okajima H; Kaido T; Sakaguchi S; Uemoto S
    J Transl Med; 2018 Apr; 16(1):95. PubMed ID: 29642912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.